NICE evaluation has suggested a cut‐off of 10 μg Hb/g faeces for low‐risk patients16, but symptomatic patients may have colorectal cancer despite fHb readings below this level: 12·5 per cent of all colorectal cancers detected in the present cohort. This evidence concerns the gene GSTM1 and colorectal cancer.